Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, raised $109 million by offering 4.7 million ADSs at $23.26. Listed on the Euronext Paris, it had provided a range of $23 to $24. The company also raised $16 million in a European private placement at €20 per share. Erytech Pharma plans to list on the Nasdaq under the symbol ERYP. Jefferies, Cowen & Company and Oddo BHF acted as lead managers on the deal.
